Advertisement

Small-Molecular-Weight Inhibitors

  • R. L. Ryall
  • P. K. Grover
  • R. M. Harnett
  • C. M. Hibberd
  • V. R. Marshall

Abstract

The potential role of inhibitors in calcium stone formation is not trivial: it may account for the fact that stones do not occur in the presence of significant urinary supersaturation. Furthermore, if stone formation could be attributed to a lack or deficiency of inhibitors, then their supplementation in the urine could form the basis of preventive therapy. Thus, numerous studies have been undertaken with the object of defining the role of inhibitors in urinary stone disease. These have included investigations of the mechanisms by which they inhibit crystallization in vitro, their excretion characteristics in stone formers and normal controls, and their influence on stone formation in vivo. For the sake of brevity, this review will be confined to a discussion of studies on calcium oxalate (CaOx), although it should be noted that much of the information known about the effects of small-molecular-weight inhibitors on the crystallization of this salt is also available for hydroxyapatite. Further, in summarizing the effects of these inhibitors on CaOx crystallization, I will distinguish between the separate phenomena of nucleation, growth (expressed in most cases as the amount of crystalline material deposited), and aggregation, since it is recognized that each of these may be separately affected by any one inhibitor. Nonetheless, it must be borne in mind that quite apart from any direct influence that an inhibitor may have on any one of these processes, by affecting only one of them, it may unavoidably influence another. For example, Fig. 1 shows the indirect effect that inhibition of just crystal aggregation may have on the amount of crystalline material deposited when crystal growth itself is not directly inhibited. The practical consequences of this will be illustrated later with regard to the inhibitory effect of magnesium.

Keywords

Calcium Oxalate Methyl Violet Magnesium Hydroxide Calcium Oxalate Crystal CaOx Crystal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H Fleisch and S Bisaz, Isolation from urine of pyrophosphate, a calcification inhibitor, Am. J. Physiol. 203: 671 (1962).PubMedGoogle Scholar
  2. 2.
    JL Meyer and LH Smith, Growth of calcium oxalate crystals II. Inhibition by natural crystal growth inhibitors, Invest. Urol. 13: 36 (1975).PubMedGoogle Scholar
  3. 3.
    M Wagner and B Finlayson, The characteristics of adsorption of pyrophosphate and citrate onto whewellite, Invest. Urol. 15: 456 (1978).PubMedGoogle Scholar
  4. 4.
    MK Li, NJ Blacklock, and J Garside, Effects of magnesium on calcium oxalate crystallization, J. Urol. 133: 123 (1985).PubMedGoogle Scholar
  5. 5.
    RH Doremus, S Teich, and PX Silvis, Crystallization of calcium oxalate from synthetic urine, Invest. Urol. 15: 469 (1978).PubMedGoogle Scholar
  6. 6.
    DJ Sutor, Growth studies of calcium oxalate in the presence of various ions and compounds, Br. J. Urol. 41: 171 (1969).PubMedCrossRefGoogle Scholar
  7. 7.
    SG Welshman and MG McGeown, A quantitative investigation of the effects on the growth of calcium oxalate crystals of potential inhibitors, Br. J. Urol. 44: 677 (1972).PubMedCrossRefGoogle Scholar
  8. 8.
    WG Robertson, M Peacock, and BEC Nordin, Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro, Clin. Chim. Acta 43: 31 (1973).PubMedCrossRefGoogle Scholar
  9. 9.
    RL Ryall, RM Harnett, and VR Marshall, The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro, Clin. Chim. Acta 112: 349 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    JF Desmars and R Tawashi, Dissolution and growth of calcium oxalate monohydrate I. Effect of magnesium and pH, Biochim. Biophys. Acta 313: 256 (1973).PubMedCrossRefGoogle Scholar
  11. 11.
    PG Werness, JH Bergert, and KE Lee, Urinary crystal growth: effect of inhibitor mixtures, Clin. Sci. 61: 487 (1981).PubMedGoogle Scholar
  12. 12.
    RL Ryall, CM Hibberd, and VR Marshall, A method for studying inhibitory activity in whole urine, Urol. Res. 13: 285 (1985).PubMedCrossRefGoogle Scholar
  13. 13.
    PC Hallson, GA Rose, and S Sulaiman, Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine, Urol. Res. 11: 151 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    PC Hallson, GA Rose, and S Sulaiman, Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine, Urol. Int. 38: 179 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    PC Hallson, GA Rose, and S Sulaiman, Magnesium reduced calcium oxalate crystal formation in human whole urine, Clin. Sci. 62: 17 (1982).PubMedGoogle Scholar
  16. 16.
    RL Ryall et al., unpublished data.Google Scholar
  17. 17.
    KA Edyvane, CM Hibberd, RM Harnett, VR Marshall, and RL Ryall, Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine, Clin. Chim. Acta 167: 329 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    WC Thomas, Use of phosphates in patients with calcareous renal calculi, Kidney Int. 13: 390 (1978).PubMedCrossRefGoogle Scholar
  19. 19.
    LH Smith, The effects of orthophosphate and ion binders, in: “Urolithiasis and Related Clinical Research”, PO Schwille, LH Smith, WG Robertson, and W Vahlensieck, eds., Plenum Press, New York (1985).Google Scholar
  20. 20.
    CYC Pak, C Skurla, GM Preninger, and F Britton, Long-term treatment of calcium nephrolithiasis with potassium citrate, J. Urol. 134: 11 (1985).PubMedGoogle Scholar
  21. 21.
    G Johansson, U Backman, BG Danielson, B Fellstrom, S Ljunghall, and B Wikstrom, Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide, J. Urol. 124: 770 (1980).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • R. L. Ryall
    • 1
  • P. K. Grover
    • 1
  • R. M. Harnett
    • 1
  • C. M. Hibberd
    • 1
  • V. R. Marshall
    • 1
  1. 1.Urology Unit, Department of SurgeryFlinders Medical CenterBedford ParkSouth Australia

Personalised recommendations